Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 6 | — | — | — | 9 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 1 | — | — | — | 3 |
Hiv | D006678 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | 2 | — | — | — | — | 2 |
Communicable diseases | D003141 | — | — | 2 | — | — | — | — | 2 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | CAPRAVIRINE |
INN | capravirine |
Description | Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer. Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.
|
Classification | Small molecule |
Drug class | antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1 |
PDB | — |
CAS-ID | 178979-85-6 |
RxCUI | — |
ChEMBL ID | CHEMBL435128 |
ChEBI ID | — |
PubChem CID | 1783 |
DrugBank | — |
UNII ID | VHC779598X (ChemIDplus, GSRS) |